¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"brainstem evoked response audiometry"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • frequency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual evoked potential
    ½Ã°¢À¯¹ßÀüÀ§
  • somatic evoked potential test
    ¸öÀ¯¹ßÀüÀ§°Ë»ç
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    (¢¡secondary immune response) ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • biologic response modifier
    »ýü¹ÝÀÀÁ¶Àý¹°Áú, »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦
  • response bias
    ¹ÝÀÀ¹ÙÀ̾
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • conditioned avoidance response
    Á¶°ÇȸÇǹÝÀÀ
  • conditioned emotional response
    Á¶°Ç°¨Á¤¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
  • inert response
    ºÒȰ¼º ¹ÝÀÀ
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§¾à¹ÝÀÀ, ¼ÓÀÓ¾à¹ÝÀÀ.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§<°¡>¾à¹ÝÀÀ.
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • pressure response
    À½¾Ð¹ÝÀÀ(ëåäâÚãëë).
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • somatosensory-evoked potential(SEP)
    ü¼º°¨°¢(-¼º) À¯¹ßÀüÀ§
  • test, evoked otoacoustic emission
    À¯¹ßÀÌÀ½Çâ¹æ»ç°Ë»ç
  • visual evoked potential
    ½ÃÀ¯¹ßÀüÀ§
  • visual evoked potential
    ½Ã°¢À¯¹ßÀüÀ§.
  • air conduction audiometry
    ±âµµÃ»·Â û°¢°Ë»ç
  • audiometry
    û·Â °Ë»ç(ôæÕôËþÞÛ)
  • audiometry
    û·Â°Ë»ç£¨¹ý£©, û·ÂÃøÁ¤
  • audiometry, Bekesy
    ÀÚ±âû·Â(°è±â)°Ë»ç
  • audiometry, EEG
    ³úÆÄû·Â°Ë»ç
  • audiometry, air conduction
    ±âµµÃ»·Â û°¢°Ë»ç
  • audiometry, automatic
    ÀÚ±âû·Â(°è±â)°Ë»ç
  • audiometry, behavioral observation
    Çൿ°üÂûû·Â°Ë»ç
  • audiometry, bone conduction
    °ñµµÃ»·Â û°¢°Ë»ç
  • audiometry, conditioned orientation reflex
    Á¶°Ç¹Ý»çû·Â°Ë»ç
  • audiometry, electrodermal
    Àü·ùÇǺιÝÀÀû·Â°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
SEP self-evaluation process; sensory-evoked potential; septum; somatosensory evoked potential; sperm ent...
BAEP brainstem auditory evoked potential
CER capital expenditure review; ceramide; conditioned emotional response; control electrical rhythm; cor...
ABR abortus Bang ring [test]; absolute bed rest; auditory brainstem response
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AABR automated auditory brainstem response
PTA Pure Tone Audiometry
VRA Visual Reinforcement Audiometry
ABI Auditory Brainstem Implant
BBE Bickerstaff s brainstem encephalitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • emotional defense response
    Á¤¼­Àû ¹æ¾î ¹ÝÀÀ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
  • immediate response
    Ãʱ⠹ÝÀÀ
    ¾Ë·¹¸£±â ¹ÝÀÀ°ú °°ÀÌ À¯¹ßÀÎÀÚ¿¡ Á¢ÇÑ ÈÄ, ¸î ÃÊ-¸î ºÐ À̳»¿¡ ÃâÇöÇÏ´Â ¹ÝÀÀ.
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
electrophysiologic audiometry Measurement of a patient's response to a sound stimulus by using various types of objective audiometric equipment or techniques without necessarily having the patient's conscious cooperation.
(05 Mar 2000)
anamnestic response <immunology> Archaic term now replaced by such terms as secondary immune response, immune memory.
(18 Nov 1997)
biological response modifier <pharmacology, oncology> A substance used in adjuvant therapy that takes advantage of the bodys own natural defense mechanisms to inhibit the growth of a tumour.
(16 Dec 1997)
biological response modifiers Substances that stimulate the body's response to infection and disease. The body naturally produces small amounts of these substances. Scientists can produce some of them in the laboratory in large amounts and use them in cancer treatment. Also called BRMs.
(12 Dec 1998)
biphasic response Two separate and distinct responses that are separated in time, immediate reaction to an antigenic challenge followed by a recurrence of symptoms after an interval of quiescence.
(05 Mar 2000)
booster response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
galvanic skin response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
recruiting response <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged.
(12 Dec 1998)
partial response <oncology> A decrease of at least 50 percent in the sum of the measurements of all evaluable target lesions or tumours seen in a study.
(16 Dec 1997)
relaxation response An integrated hypothalamic reaction resulting in decreased sympathetic nervous system activity which, physiologically and psychologically, is almost a mirror image of the body's response's to Cannon's emergency theory (flight or fight response); can be self-induced through the use of techniques associated with transcendental meditation, yoga, and biofeedback.
See: emergency theory.
(05 Mar 2000)
response An action or movement due to the application of a stimulus.
Origin: L. Respondere = to answer, reply
(18 Nov 1997)
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á